Stock listing

CSE:OPTI Optimi Health Corp. Stock

Home listing (CSE) of Optimi Health Corp.

Follow Optimi Health Corp. into a list and get an email when it puts out news.

Share price · CSE:OPTI

$2.30 CAD -0.31 (-11.9%)

Close on Nov 20, 2026

Past year -79.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.25 – $2.61 CADNov 20, 2026
Volume
7,334 sharesNov 20, 2026
Market cap
$13.17M CADAt the close on Nov 20, 2026 · price × 5.73M shares outstanding
52-week range
$2.25 – $12.15 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$25,481 CADMedian day 4,080 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Optimi Health Corp. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
CSE:OPTI · Home$2.30 CAD-0.31 (-11.9%)7,334$2.61$2.61$2.25$2.61Close on Nov 20, 2026
NASDAQ:OPTH$1.51 USD-0.24 (-13.7%)26,030$1.73$1.85$1.51$1.75Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:OPTI · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.30-0.31-11.9%$2.61$2.61$2.257,334
$2.61-0.39-13.0%$3.00$3.00$2.614,135
$3.00-0.10-3.2%$3.10$3.14$2.803,354
$3.10-0.10-3.1%$3.20$3.27$2.9515,500
$3.20+0.06+1.9%$3.13$3.29$3.0010,146
$3.14-0.26-7.6%$3.40$3.40$3.106,692
$3.40+0.17+5.3%$3.30$3.40$3.094,005
$3.23-0.27-7.7%$3.63$3.63$3.2311,123
$3.50+0.23+7.0%$3.30$3.60$3.158,462
$3.27+0.14+4.5%$3.30$3.36$3.271,289
$3.13+0.07+2.3%$3.15$3.26$2.9913,651
$3.06+0.11+3.7%$3.00$3.06$2.7111,853
$2.95-0.25-7.8%$3.20$3.20$2.908,629
$3.20-0.40-11.1%$3.60$3.60$3.204,209
$3.60-0.02-0.6%$3.65$3.65$2.9612,213
$3.62-0.28-7.2%$3.93$3.93$3.548,536
$3.90-0.35-8.2%$4.30$4.30$3.902,023
$4.25-0.15-3.4%$4.36$4.36$4.25917
$4.40-0.10-2.2%$4.50$4.50$4.402,306
$4.50-0.13-2.8%$4.60$4.64$4.50938
$4.63-0.12-2.5%$4.81$4.85$4.631,928
$4.750.000.0%$4.75$4.75$4.704,080
$4.75+0.05+1.1%$4.66$4.75$4.661,045
$4.70-0.04-0.8%$4.84$5.00$4.675,486
$4.74+0.19+4.2%$4.61$4.75$4.612,400
$4.55+0.07+1.6%$4.50$4.63$4.456,747
$4.48-0.52-10.4%$4.78$4.78$4.359,541
$5.00-0.70-12.3%$5.50$5.50$4.878,440
$5.70-0.09-1.6%$5.83$5.85$5.704,611
$5.79-0.015-0.3%$5.81$5.95$5.791,690
$5.805-0.095-1.6%$5.95$5.95$5.744,080
$5.90-0.40-6.3%$6.30$6.30$5.852,734
$6.30-0.10-1.6%$6.40$6.40$6.012,812
$6.40-0.15-2.3%$6.61$6.61$6.401,181
$6.55-0.20-3.0%$6.84$6.84$6.552,251
$6.75-0.01-0.1%$6.90$6.90$6.752,052
$6.76-0.09-1.3%$6.92$6.92$6.654,800
$6.850.000.0%$6.92$6.93$6.802,022
$6.85+0.03+0.4%$6.98$6.98$6.851,107
$6.82-0.19-2.7%$7.07$7.07$6.791,800
$7.01-0.04-0.6%$7.07$7.20$7.011,740
$7.05+0.24+3.5%$6.85$7.10$6.856,725
$6.81-0.13-1.9%$6.96$6.96$6.764,356
$6.94+0.01+0.1%$6.81$6.94$6.613,160
$6.93+0.03+0.4%$7.00$7.00$6.784,639
$6.90-0.30-4.2%$7.06$7.08$6.7513,060
$7.20+0.60+9.1%$6.58$7.20$6.2919,298
$6.60+0.49+8.0%$6.19$6.60$6.197,331
$6.11-0.09-1.5%$6.27$6.40$6.112,905
$6.20+0.15+2.5%$6.05$6.34$5.804,420
$6.05-0.51-7.8%$6.74$6.77$6.0510,112
$6.56-0.07-1.1%$6.80$6.80$6.505,872
$6.63-0.01-0.2%$6.68$6.68$6.63856
$6.64+0.12+1.8%$6.65$6.65$6.62312
$6.52-0.28-4.1%$6.85$6.85$6.517,204
$6.80+0.10+1.5%$6.82$6.82$6.711,700
$6.70-0.15-2.2%$6.91$6.91$6.701,431
$6.85-0.01-0.1%$6.90$6.90$6.85300
$6.86+0.08+1.2%$6.80$6.86$6.715,805
$6.78-0.05-0.7%$6.83$6.85$6.771,700
$6.83+0.10+1.5%$6.91$6.91$6.83500
$6.73-0.09-1.3%$6.94$6.94$6.732,900
$6.82+0.15+2.2%$6.75$6.95$6.7011,933
$6.67+0.04+0.6%$6.74$6.74$6.601,200

Splits

1 split · CSE:OPTI · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
CSE:OPTI
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
CSE
Currency
CAD

What changed lately

Latest news

All Optimi Health Corp. news

Optimi Health Corp. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
31 in the last 12 months · 38 in all · newest Nov 18, 2026 · oldest 2025
Decks
7 decks · latest November 2026

Where Optimi Health Corp. is listed

ListingExchangeCountryCurrency
CSE:OPTI · Home listing · This pageCSECanadaCAD
NASDAQ:OPTHNASDAQUnited StatesUSD
Cboe Canada:OPTICboe CanadaCanadaCAD
gettex:8BNgettexGermanyEUR
Lang & Schwarz:A2QQELLang & SchwarzGermanyEUR
LS Exchange:A2QQELLS ExchangeGermanyEUR
BOATS:OPTHBOATSUnited StatesUSD
Frankfurt:8BN0FrankfurtGermanyEUR
Lang & Schwarz:A411WCLang & SchwarzGermanyEUR
LS Exchange:A411WCLS ExchangeGermanyEUR
gettex:8BN0gettexGermanyEUR
Hamburg:8BN0HamburgGermanyEUR
Munich:8BN0MunichGermanyEUR
Stuttgart:8BNStuttgartGermanyEUR
Stuttgart:8BN0StuttgartGermanyEUR
Tradegate:8BN0TradegateGermanyEUR

Valuation

EV/sales 0.6× against a median of 0.7×: 5th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$96,161 CAD
P/E
Loss
EV/sales
0.6×
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
−175.4%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P/TSX Composite
1.08

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Optimi Health Corp. · CSE:OPTIUS$9.18MUS$67,058n/a0.6×n/a0.8×n/a0.0×1.08
Bal Pharma Limited · NSE:BALPHARMAUS$14.30MUS$14.30M18.4×0.4×3.9×1.6×2.1%0.0×n/a
Daesung Microbiological Laboratories Co., Ltd. · KRX:036480US$14.23MUS$18.69M54.3×1.0×13.5×0.6×1.4%0.4×n/a
Turk Ilac ve Serum Sanayi AS · BIST:TRILCUS$14.16MUS$22.15M7.7×0.2×0.6×0.4×1.6%0.2×n/a
PT Phapros Tbk · IDX:PEHAUS$12.79MUS$41.58M4.5×0.7×4.6×0.5×5.0%1.5×n/a
PT Ikapharmindo Putramas Tbk · IDX:IKPMUS$11.81MUS$10.76Mn/an/an/a0.9×n/a0.0×n/a
Alpa Laboratories Limited · NSE:ALPAUS$11.33MUS$11.33M24.0×0.9×12.2×0.6×3.8%0.0×n/a
Advicenne SA · EURONEXT:ALDVIUS$10.53MUS$32.08Mn/a4.9×n/an/a−158.7%n/an/a
Biofrontera Inc. · NASDAQ:BFRIUS$9.51MUS$13.83Mn/a0.3×n/an/a−12.7%n/a1.96
ChoA Pharmaceutical Co., Ltd. · KRX:034940US$6.59MUS$6.89Mn/a0.1×n/a0.3×−4.6%0.1×n/a
Newbury Pharmaceuticals AB · OMXSTO:NEWBRYUS$5.78MUS$4.87Mn/a1.2×n/a3.0×−53.7%0.0×n/a
Median of the othersUS$11.57MUS$14.06M18.4×0.7×4.6×0.6×1.4%0.0×1.96

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
15.00 CAD · Analysts' mean
EPS, year to Sep 2026
-1.42 · 1 analyst
Revenue, year to Sep 2026
665.7K · 1 analyst

Team and board

Officers

OfficerRole
Dane StevensDirector — Chief Executive Officer & Co-Founder
Jacob SafarikChief Financial Officer & Director
Bryan SafarikChief Operating Officer & Director
Karina LahnakoskiDirector of Quality and Commercial Strategies
Michael BloughChief Clinical Development Officer
Preston ChaseChief Science Officer

Board

DirectorRole
JJ WilsonChairman of the Board
Bryan SafarikChief Operating Officer & Director
Dane StevensDirector — Chief Executive Officer & Co-Founder
Jacob SafarikChief Financial Officer & Director
Jason MosberianIndependent Director
John James WilsonDirector

Events

QuarterResultsShare move
Q3 2026Aug 14, 2026 · After close−0.8%
Q2 2026Jun 1, 2026 · After close+2.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck16 slidesNovember 2026
Investor Presentation (September 2026)Investor deck22 slidesSeptember 2026
Investor Presentation (August 2024)Investor deck22 slidesAugust 2024
Investor Presentation (November 2022)Investor deck28 slidesNovember 2022
Investor Presentation (January 2022)Investor deck23 slidesJanuary 2022
Investor Presentation (November 2021)Investor deck23 slidesNovember 2021
IPO Roadshow (January 2021)IPO roadshow22 slidesJan 15, 2021

Open Decks

Financings

RaiseDateIn US dollars
Common shares (equity line of credit)
Announced: up to US$100M · Joseph Gunnar & Co. LLC
Dealers: Joseph Gunnar & Co. LLC (lead)
Buyers: Seven Knots, LLC (up to US$100 million of common shares from time to time under the ELOC)
Aug 14, 2026
Public offering of common shares
Update: Joseph Gunnar & Co., LLC
Dealers: Joseph Gunnar & Co., LLC (lead)
Apr 23, 2026
Public offering of common shares
Announced: Titan Partners Group, a division of American Capital Partners
Dealers: Titan Partners Group, a division of American Capital Partners (lead)
Sep 8, 2025
Private placement of unsecured convertible debentures
Announced: C$3.45M · C$1,000
Buyers: Dane Stevens (Following the acquisition holds 11,875,566 Common Shares or 12.29% of the Company); JJ Wilson (Following the acquisition holds 8,237,501 Common Shares or 8.52% of the Company)
Insiders: The Investors are Dane Stevens, CEO, CMO and a director, and JJ Wilson, Chair of the Board and a director; a related party transaction under MI 61-101
Use of proceeds: General working capital
Jul 18, 2025US$2.51M

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$6.25 a share on May 19, 2026.

Price
US$6.25 a share
Shares offered
2,400,000 common shares
Offering size
US$15 million
Underwriters' option
Up to 360,000 more shares
Listing
OPTH on the Nasdaq Capital Market
Underwriter
Joseph Gunnar & Co., LLC
Shares delivered
On or about May 21, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJun 16, 2025
Filed publiclySep 5, 2025
Amended 8 timesNewest May 19, 2026
Shares registered with an exchangeMay 19, 2026
Declared effective by the SECMay 19, 2026
Final prospectus, with the priceMay 20, 2026

Open IPO · From the cover of the final prospectus (424B4) filed May 20, 2026

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue426.3K389.9K181.1K80.7K0
Cost of revenue494.4K118.9K-19.1K26.8K0
Gross profit-68.1K270.9K200.2K53.9K0
Research and development347.7K387.6K152.1K133.2K240.9K
Selling, general and administrative2.72M3.85M3.82M7.02M5.77M
Operating income-4.61M-5.61M-5.27M-7.39M-6.06M
Depreciation and amortization950.3K867.9K729.6K293.6K47.1K16.3K
EBITDA-3.66M-4.74M-4.54M-7.10M-6.01M
Interest expense531.7K429.3K43.7K28.0K19.2K0
Income before tax-3.71M-6.04M-5.19M-7.35M-6.02M
Net income-3.71M-6.04M-5.19M-7.35M-6.02M
Earnings per share, basic-1.15-1.91-0.06-0.09-0.09

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents1.15M103.7K1.34M1.89M8.43M4.47M
Short-term investments04.00M0
Receivables95.1K124.1K165.7K98.7K188.2K83.2K
Inventory310.4K894.8K779.3K264.7K123.2K
Current assets1.83M1.23M2.43M2.43M14.3M4.62M
Property, plant and equipment14.4M8.90M1.52M
Total assets15.2M14.6M16.5M16.8M23.5M6.17M
Accounts payable1.19M749.4K901.9K556.0K2.11M647.3K
Current liabilities8.48M3.22M1.61M728.2K2.24M751.8K
Long-term debt1.76M1.64M
Total liabilities8.64M4.98M3.28M797.7K2.40M882.7K
Shareholders' equity6.57M9.58M13.2M16.0M21.1M5.29M
Shares outstanding3.22M3.16M87.0M80.9M69.9M69.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-2.63M-4.28M-3.60M-4.58M-6.02M-422.4K
Capital spending-88.4K-152.4K-804.2K-7.15M-4.94M-2.26M
Free cash flow-2.72M-4.43M-4.41M-11.7M-11.0M-2.69M
Cash from investing-3.15M-9.19M-2.26M
Cash from financing3.76M3.19M3.76M1.19M19.2M16.1M
Change in cash1.04M-1.24M-543.8K-6.54M3.96M13.4M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 18, 2026Current reportSEC
6-K · Report of a foreign issuerOct 26, 2026Current reportSEC
6-K · Report of a foreign issuerOct 20, 2026Current reportSEC
6-K · Report of a foreign issuerOct 7, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 5, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerSep 29, 2026Current reportSEC
6-K · Report of a foreign issuerSep 23, 2026Current reportSEC
6-K · Report of a foreign issuerSep 22, 2026Current reportSEC
6-K · Report of a foreign issuerSep 16, 2026Current reportSEC
6-K · Report of a foreign issuerSep 10, 2026Current reportSEC
All 48 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerSep 8, 2026Current reportSEC
424B3 · ProspectusAug 27, 2026Offer documentSEC
6-K · Report of a foreign issuerAug 26, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveAug 26, 2026Other filingsSEC
F-1 · Registration statementAug 14, 2026Offer documentSEC
6-K · Report of a foreign issuerAug 14, 2026Current reportSEC
6-K · Report of a foreign issuerAug 14, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerAug 7, 2026Current reportSEC
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
6-K · Report of a foreign issuerJul 20, 2026Current reportSEC
S-8 · Registration statement for employee plansJul 7, 2026Offer documentSEC
6-K · Report of a foreign issuerJun 29, 2026Current reportSEC
6-K · Report of a foreign issuerJun 16, 2026Current reportSEC
6-K · Report of a foreign issuerJun 10, 2026Current reportSEC
6-K · Report of a foreign issuerJun 8, 2026Current reportSEC
6-K · Report of a foreign issuerJun 2, 2026Current reportSEC
6-K · Report of a foreign issuerJun 1, 2026Current reportSEC
6-K · Report of a foreign issuerMay 29, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 27, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerMay 26, 2026Current reportSEC
424B4 · ProspectusMay 20, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 20, 2026Other filingsSEC
CERT · Exchange's certificate of listingMay 19, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeMay 19, 2026Other filingsSEC
F-1/A · Registration statement, amendedMay 19, 2026Offer documentSEC
F-1/A · Registration statement, amendedApr 23, 2026Offer documentSEC
F-1/A · Registration statement, amendedApr 21, 2026Offer documentSEC
F-1/A · Registration statement, amendedApr 21, 2026Offer documentSEC
F-1/A · Registration statement, amendedApr 16, 2026Offer documentSEC
F-1/A · Registration statement, amendedMar 24, 2026Offer documentSEC
F-1/A · Registration statement, amendedMar 13, 2026Offer documentSEC
F-1/A · Registration statement, amendedFeb 17, 2026Offer documentSEC
F-1 · Registration statementSep 5, 2025Offer documentSEC
DRS/A · Draft registration statement, amendedAug 7, 2025Offer documentSEC
DRS · Draft registration statementJun 13, 2025Offer documentSEC
DAug 26, 2024Other filingsSEC
DJun 26, 2024Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Optimi Health Corp.’s releases · as of Aug 14, 2026

Common shares
5,725,867
Fully diluted
5,725,867

Fully diluted

LineSharesAs of
Common shares5,725,867Jun 30, 2026

Share count over time

CountShares
Jun 30, 20265,725,867

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
AdvisorShares Investments LLC260K4.5%US$1.23MSep 30, 2026
Yorkville Advisors Global, LP173K3.0%US$815KSep 30, 2026
Mariner, LLC122K2.1%US$208Sep 30, 2026
StoneX Group Inc.11,0410.19%US$53,365Sep 30, 2026
RBC3,3420.06%US$15,000Sep 30, 2026
UBS2,1150.04%US$9,962Sep 30, 2026
National Bank Of Canada501<0.01%US$2,351Sep 30, 2026
TD333<0.01%US$1,523Sep 30, 2026
Northwestern Mutual Wealth Management Co136<0.01%US$641Sep 30, 2026
Arax Advisory Partners50<0.01%US$236Sep 30, 2026
All 11 holders
HolderSharesOf the companyValueAs of
Rydar Equities, Inc.33<0.01%US$133Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
AdvisorShares Psychedelics ETF103K1.8%US$523KJun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Dane Nicholas Stevens
Director of Issuer
Buy5,000CAD 6.93CAD 34,650Sep 1, 2026
Dane Nicholas Stevens
Director of Issuer
Buy3,800CAD 6.66CAD 25,308Aug 5, 2026
Dane Nicholas Stevens
Director of Issuer
Buy700CAD 6.92CAD 4,844Jul 16, 2026
Dane Nicholas Stevens
Director of Issuer
Buy3,000CAD 6.95CAD 20,850Jul 16, 2026
Dane Nicholas Stevens
Director of Issuer
Buy15,000CAD 6.31CAD 94,650Jul 15, 2026
Bryan Edward Safarik
Director of Issuer
Buy4,000CAD 0.29CAD 1,160Mar 27, 2026
Dane Nicholas Stevens
Director of Issuer
Buy100,000CAD 0.28CAD 28,000Mar 18, 2026
Dane Nicholas Stevens
Director of Issuer
Buy100,000CAD 0.28CAD 28,500Mar 18, 2026
Dane Nicholas Stevens
Director of Issuer
Buy70,000CAD 0.34CAD 23,800Feb 13, 2026
Dane Nicholas Stevens
Director of Issuer
Buy32,000CAD 0.34CAD 10,880Feb 10, 2026
All 14 trades
TradeTradeSharesPriceValueDate
Dane Nicholas Stevens
Director of Issuer
Buy18,000CAD 0.34CAD 6,120Feb 9, 2026
Jason Mosberian
Director of Issuer
Option exercise26,250CAD 0.29CAD 7,613Jan 30, 2026
Dane Nicholas Stevens
Director of Issuer
Buy9,000CAD 0.32CAD 2,880Jan 22, 2026
Dane Nicholas Stevens
Director of Issuer
Buy102,500CAD 0.32CAD 32,800Jan 20, 2026

Big stakes

StakeStakeSharesDateFiling
Cathay Visions Enterprises Inc.8.25%474KMay 19, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bryan SafarikChief Operating Officer & Director · Since at least Nov 5, 2026
Dane StevensDirector — Chief Executive Officer & Co-Founder · Since at least Oct 26, 2026
Jacob SafarikChief Financial Officer & Director · Since at least Nov 5, 2026
Jason MosberianIndependent Director · Since at least Dec 18, 2025
JJ WilsonChairman of the Board · Since at least Mar 16, 2026
John James WilsonDirector · Since at least Nov 5, 2026
Karina LahnakoskiDirector of Quality and Commercial Strategies · Since at least Nov 5, 2026
Michael BloughChief Clinical Development Officer · Since at least Nov 5, 2026
Preston ChaseChief Science Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Optimi Health Corp.